Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H29F2N5O3 |
Molecular Weight | 557.5905 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(=CC(F)=C1)[C@@H]2CNC3(CCCC3)C(=O)N2CC(=O)NC4=CC5=C(C[C@]6(C5)C(=O)NC7=NC=CC=C67)C=C4
InChI
InChIKey=AZAANWYREOQRFB-SETSBSEESA-N
InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)/t25-,30+/m0/s1
Molecular Formula | C31H29F2N5O3 |
Molecular Weight | 557.5905 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20065019Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21383045
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20065019
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21383045
MK-3207 represents the third CGRP receptor antagonist to display clinical efficacy in migraine trials. It is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. MK-3207 had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of migraine. But the company had discontinued the research due to asymptomatic liver test abnormalities in 2010.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800029725
Curator's Comment: # Merck & Co
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
979 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20065019 |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
MK-3207 plasma | Macaca mulatta population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3285 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20065019 |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
MK-3207 plasma | Macaca mulatta population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24900170 |
MK-3207 plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00712725
2.5 - 100 mg taken after migraine onset orally
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20065019
MK-3207 potently inhibits human α-CGRP-induced cAMP production in HEK293 cells stably expressing human CLR/RAMP1 with an IC50 of 0.12 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:21:20 GMT 2023
by
admin
on
Fri Dec 15 17:21:20 GMT 2023
|
Record UNII |
5C44M1QYCC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25019940
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
300000041501
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
5C44M1QYCC
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
957118-49-9
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
DB12424
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL1910936
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY | |||
|
DTXSID00241931
Created by
admin on Fri Dec 15 17:21:20 GMT 2023 , Edited by admin on Fri Dec 15 17:21:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|